Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Pediatr Blood Cancer. 2014 Sep 24;62(1):45–51. doi: 10.1002/pbc.25229

Figure 3.

Figure 3

An 11 yo patient (also shown in Figs 24; see note * below) with progressive physeal widening during pazopanib therapy (A–C), and reversibility of these changes once therapy was stopped (D–F). A–C: While on therapy the patient received 10 courses of pazopanib, after which therapy was stopped. Note the progressive widening of the distal femoral growth plates (arrows) as therapy continued. D–F: Once therapy stopped, growth plate maturation resumed, the distal femoral physis gradually closed, and had almost completely fused (F) less than one year after stopping anti-angiogenic therapy. Transverse metaphyseal bands of sclerosis reflect growth recovery lines. * Note: Images from this patient were also shown in the primary publication summarizing clinical results of the Phase 1 pazopanib study (ADVL0815) [22]; those images were from either a different study timepoint or MR series. No images have been directly reproduced here.